Product Information
| Property | Description |
|---|---|
| Product Name | Anti-mouse PPARδ Recombinant Monoclonal Antibody |
| Antibody ID | MM0052 |
| Target Protein | Peroxisome proliferator-activated receptor delta (PPARδ / PPARD) |
| UniProt Accession | Mouse: P35396 |
| Molecular Weight | Mouse: 49.7 kDa |
| Antibody Type | Recombinant monoclonal antibody |
| Host Species | Mouse |
| Recombinant Format | Full-length mouse IgG1 |
| Isotype | Mouse IgG1 |
| Species Reactivity | Mouse |
| Tested Applications | WB |
| Recommended Dilution for WB | 1:500–1:5000 |
| Antigen | Recombinant epitope-Fc fusion protein |
| Epitope Sequence | QEETPEAREEEKEEVAMGDG |
| Expression System | HEK293 cells |
| Purification | Protein G affinity chromatography |
| Conjugate | Unconjugated |
| Concentration | 0.1 mg/mL |
| Storage Buffer | 0.1 M Tris, 0.05 M Glycine, 0.07 M NaCl, 2 g/L BSA, 50% glycerol, pH 7 |
| Storage Condition | Store at -20°C. |
| Research Use | For research use only. Not for diagnostic or therapeutic applications. |
Product Background
Peroxisome proliferator-activated receptor delta (PPARδ / PPARD) is a ligand-activated nuclear receptor involved in lipid metabolism, glucose homeostasis, mitochondrial function, inflammation, energy balance, and skeletal muscle physiology. PPARδ plays important roles in metabolic regulation, cardiovascular biology, fatty acid oxidation, and transcriptional control.
PPARδ is widely studied in metabolism research, obesity, diabetes, cardiovascular biology, exercise physiology, inflammation, and nuclear receptor signaling pathways.
Antibody Development
MM0052 was generated by phage-display selection using a mouse-derived antibody library. Recombinant epitope-Fc fusion protein containing the PPARδ epitope sequence was used as the selection antigen. Following identification of the initial antibody candidate, structure-guided affinity optimization was performed to improve binding affinity and specificity.
The optimized antibody was reconstructed as a full-length mouse IgG1 recombinant antibody and expressed in HEK293 cells.
Binding and specificity were evaluated by:
- ELISA using recombinant epitope-Fc fusion antigen
- Western blot using recombinant MBP-epitope fusion protein
- Western blot detection of endogenous mouse PPARδ protein in tissues
Validation Data
ELISA Validation
ELISA demonstrated specific binding to recombinant epitope-Fc fusion antigen, while minimal binding was observed against Fc control protein.
Validation conditions:
- Well 1: Fc control protein
- Well 2: Epitope-Fc fusion protein
- Detection substrate: TMB
Note:
ELISA validation confirms binding to the epitope-Fc fusion antigen. Full-length PPARδ protein binding in solution has not been tested by ELISA.
Western Blot Validation – Recombinant Fusion Protein
Western blot analysis demonstrated specific recognition of recombinant MBP-epitope fusion protein expressed in BL21(DE3) cells, while no significant binding was observed against MBP control protein.
Validation conditions:
- Lane 1: MBP control protein
- Lane 2: MBP-epitope fusion protein
- Standard reducing Western blot
Western Blot Validation – Endogenous Full-Length Protein
Western blot analysis detected endogenous PPARδ protein in mouse liver, heart, and brain tissues under reducing conditions.
Validated samples:
- Mouse liver tissue
- Mouse heart tissue
- Mouse brain tissue
Detection condition:
- Standard reducing Western blot
- HRP-conjugated anti-mouse secondary antibody
Observed bands:
- Major bands observed near expected PPARδ molecular weight















